HLA-C and cancer: The abundance of NK cells, along with their surface inhibitory receptor KIR2DL, is elevated in patients with hepatoblastoma, potentially because the HLA‐C molecules on tumour cells bind to KIR2DL and suppress NK cytotoxicity, which leads to cancer cell immune escape.19